DUBAI & WOBURN, Mass.
Courtagen Life Sciences Inc. announced today they have signed an exclusive strategic distribution agreement with the Alliance Global Group (AGBL) to help clinicians in emerging markets diagnose and manage a number of genetically based disorders. Courtagen’s test menu currently offers clinical tests for mitochondrial disorders (mtSEEK™ and nucSEEK™) and a newly released panel for epilepsy and seizure (epiSEEK™). Courtagen plans to add a number of key tests for other important neurological disorders.
“Building this relationship with AGBL is a critical component of Courtagen’s international business expansion,” said Brian McKernan, CEO, Courtagen Life Sciences, Inc.
Courtagen’s CLIA Laboratory genetic tests use next generation sequencing (NGS) technology, propriety bioinformatics platform, ZiPhyr™ and state of the art analytic capabilities to accurately sequence patient’s DNA and translate the sequence data into highly useful, clinically relevant information for physicians. Additionally, Courtagen’s protein diagnostics division offers decentralized testing of protein biomarker to simplify pre-clinical and clinical trial protocols.
“We are pleased to enter into this agreement with Courtagen,” said Dr. Tamer Degheidy, CEO of Alliance Global. “Courtagen’s portfolio of genetic tests will certainly have a positive impact on patients’ diagnosis and management in markets covered by our group.”
About Courtagen Life Sciences Inc.
Based in Woburn, Massachusetts (USA), Courtagen Life Sciences is a privately held life sciences company that provides innovative proteomic and genomic products and services to the life sciences industry. Founded by innovators in next-generation sequencing, genetics, molecular biology, and information science, the company delivers tools to enable researchers and clinicians to make better decisions regarding drug development and patient care. For more information, please visit: www.courtagen.com
About Alliance Global Group (AGBL)
The AGBL Group of companies is the largest biomedical gateway to the emerging markets of Middle East, Africa and Asia. The group is dedicated to bringing the latest technologies and products to researchers, clinicians, diagnostic users and healthcare providers in the markets it covers. The group employs more than 80 specialists and has six regional offices offering distribution, consultation and product development services. The company helps biomedical technology manufacturers and suppliers introduce their products and services to emerging markets, reflecting on the healthcare standards within those markets. For more information, please visit: www.agbl.net
CONTACT
Courtagen Life Sciences Inc.
Elizabeth Holland, +1
617-892-7178
Vice President, Business Operations
Elizabeth.holland@courtagen.com
or
Alliance
Global Group
info@agbl.net
